January 10, 2017
Japanese Takeda in a $5.2 billion acquisition deal with USA-based Ariad
Takeda has ensured the signature to buy USA-based drugmaker focused on producing cancer treatments, Ariad Pharmaceuticals for about $5.2 billion, or $24 per share in cash for stockholders.